Mamizadeh Mina, Maleki Farajolah, Mohammadi Mohammad Reza, Shamsi Laya, Asghari Ali, Pouryousef Ali
Department of Dermatology, School of Medicine, Ilam University of Medical Sciences, Ilam, Iran.
Zoonotic Diseases Research Center, Ilam University of Medical Sciences, Ilam, Iran.
Parasite Epidemiol Control. 2025 Mar 7;29:e00421. doi: 10.1016/j.parepi.2025.e00421. eCollection 2025 May.
This study aimed to assess the global seroprevalence of IgG and IgM antibodies against () in solid organ transplant (SOT) recipients (kidney, liver, heart) through a literature review of studies published until October 24, 2024. Selected studies reported data on anti- IgG and IgM seroprevalence in the post-transplant stage of SOT recipients. A random-effects model estimated pooled seroprevalence rates, and heterogeneity was evaluated using the I statistic. Sensitivity analysis examined prevalence changes after excluding studies, while subgroup analysis of IgG seroprevalence accounted for publication years, countries, continents, WHO regions, sample sizes, and types of transplanted organs. Out of 26 articles and 29 datasets analyzed, 21 articles and 24 datasets involving 19,391 transplant recipients and 880 controls were used to assess anti- IgG and IgM seroprevalence and odds ratios (ORs). Additionally, 8 articles reported the anti- IgG serostatus of donors and recipients. The pooled IgG seropositivity for in SOT recipients was 9.8 % (95 % CI, 4.7-19.4 %), showing significant variation by region and organ type. The anti- IgM seroprevalence in SOT recipients was 6.4 % (95 % CI, 3.3-12 %). Renal transplant recipients exhibited higher IgG seroprevalence compared to liver and heart transplant recipients. The pooled OR for infections in SOT recipients vs. controls was 1.39 (95 % CI, 0.95-2.04, = 0.08). The highest pooled anti- IgG serostatus was 50.7 % in the undetermined group, followed by 38 % in the D-/R- group, 15.4 % in the D-/R+ group, 10.6 % in the D+/R- group, and 9.9 % in the D+/R+ group. Overall, active infections and its increased risk trend in SOT recipients should not be overlooked.
本研究旨在通过对截至2024年10月24日发表的研究进行文献综述，评估实体器官移植（SOT）受者（肾、肝、心）中针对（）的IgG和IgM抗体的全球血清阳性率。入选研究报告了SOT受者移植后阶段抗IgG和IgM血清阳性率的数据。采用随机效应模型估计合并血清阳性率，并使用I统计量评估异质性。敏感性分析在排除研究后检查患病率变化，而IgG血清阳性率的亚组分析考虑了发表年份、国家、大洲、世卫组织区域、样本量和移植器官类型。在分析的26篇文章和29个数据集中，21篇文章和24个数据集涉及19391名移植受者和8个对照组，用于评估抗IgG和IgM血清阳性率及比值比（OR）。此外，8篇文章报告了供体和受者的抗IgG血清状态。SOT受者中针对的合并IgG血清阳性率为9.8%（95%CI，4.7-19.4%），显示出按区域和器官类型有显著差异。SOT受者中抗IgM血清阳性率为6.4%（95%CI，3.3-12%）。与肝和心移植受者相比，肾移植受者表现出更高的IgG血清阳性率。SOT受者与对照组相比感染的合并OR为1.39（95%CI，0.95-2.04，=0.08）。在未确定组中最高的合并抗IgG血清状态为50.7%，其次是D-/R-组中的38%，D-/R+组中的15.4%，D+/R-组中的10.6%，以及D+/R+组中的9.9%。总体而言，SOT受者中的活动性感染及其增加的风险趋势不应被忽视。
